Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...

Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...